Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Lung Cancer. 2015 Sep 15;90(2):182–190. doi: 10.1016/j.lungcan.2015.09.014

Figure 5. Effect of C188-9 and PL on A549 xenograft tumor volume, tumor weight, pSTAT3 levels, and expression of downstream STAT3 gene targets.

Figure 5

Tumor volumes (A) or weights (B) were measured on the days indicated or following treatment for 3 weeks, respectively, with C188-9 (50mg/kg IP twice daily; n=12), PL (30mg/kg IP daily; n=11), or vehicle (n=17). The mean ± SD for each group is shown. In panel A, asterisk (*) or caret (^) indicates a reduction compared to vehicle in animals treated with C188-9 (p<0.04) or with PL (p<0.04), respectively. In panel B, the asterisk (*) indicates p<0.05. C) Levels of pSTAT3 and GAPDH levels were determined using Luminex beads in protein extracts of tumors; pSTAT3 levels were normalized for GAPDH and the mean ± SD shown; the asterisk (*) indicates a reduction in pSTAT3 levels in C188-9- or PL-treated tumors compared to vehicle (p<0.039). D) Levels of STAT3 downstream genes targets were assessed by RT-PCR in total tumor RNA. Mean ± SD is shown; an asterisk (*) indicates a significant reduction in Bcl-2 (p<0.05), Bcl-xL (p<0.045), Cyclin D1 (p<0.022) and Survivin (p<0.02) RNA levels in C188-9- and PL-treated tumors compared to vehicle-treated tumors.